A5043941523- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Dementia and Cognitive Impairment Research
- HIV/AIDS drug development and treatment
- Hepatitis C virus research
- Medical Malpractice and Liability Issues
- Neural Networks and Applications
- Lipoproteins and Cardiovascular Health
- Model Reduction and Neural Networks
- Statistical Methods in Clinical Trials
- Gaussian Processes and Bayesian Inference
- Healthcare cost, quality, practices
- Endoplasmic Reticulum Stress and Disease
- Cardiac Health and Mental Health
- Hepatitis B Virus Studies
- Hormonal Regulation and Hypertension
- HIV Research and Treatment
- Heart Rate Variability and Autonomic Control
- Systemic Lupus Erythematosus Research
- Blood Pressure and Hypertension Studies
- Liver Disease Diagnosis and Treatment
- Nuclear Receptors and Signaling
- Pharmaceutical Economics and Policy
- Cancer, Lipids, and Metabolism
- Healthcare Policy and Management
AstraZeneca (United States)
2018-2022
AstraZeneca (Sweden)
2022
Jacksonville Center for Clinical Research
2022
Statistics Collaborative
2007-2016
Aetna (United States)
2007
Iowa State University
1998
Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living. Current treatments provide only minor symptomatic improvements with limited benefit duration. Lanabecestat, brain-permeable inhibitor human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course AD slowing progression.To assess whether lanabecestat slows progression compared placebo in patients...
Standard methods for computing prediction intervals in nonlinear regression can be effectively applied to neural networks when the number of training points is large. Simulations show, however, that these generate unreliable on smaller datasets network trained convergence. Stopping algorithm prior convergence, avoid overfitting, reduces effective parameters but lead are too wide. We present an alternative approach estimating using weight decay fit and show via a simulation study this method...
Abstract In nonalcoholic fatty liver disease (NAFLD) the patatin‐like phospholipase domain‐containing 3 ( PNPLA3 ) rs738409 variant is a contributor. mice, Pnpla3 148M accumulates on lipid droplets and probably leads to sequestration of lipase cofactor leading impaired mobilization triglycerides. To advance our understanding localization abundance protein in humans, we used biopsies from patients with NAFLD investigate link genotype. We experimentally qualified an antibody against human...
The extent to which liability costs cause physicians restrict their scope of practice or cease practicing is controversial in policy debates over malpractice “crises.” We used insurance department administrative data analyze specialist physician scope-of-practice changes and exits Pennsylvania 1993–2002. In most specialties the proportions high-risk specialists restricting did not increase during crisis; however, supply obstetrician-gynecologists decreased by 8 percent three years following...
Standard methods for computing prediction intervals in nonlinear regression can be effectively applied to neural networks when the number of training points is large. Simulations show, however, that these generate unreliable on smaller datasets network trained convergence. Stopping algorithm prior convergence, avoid overfitting, reduces effective parameters but lead are too wide. We present an alternative approach estimating using weight decay fit and show via a simulation study this method...
Introduction: Elevated blood levels of lipoprotein(a) [Lp(a)] are an independent causal risk factor for atherosclerotic cardiovascular disease. Lp(a) particles formed by a lipid domain and apolipoprotein B (apoB) protein that is bound to apolipoprotein(a). Standard low-density lipoprotein cholesterol (LDL-C) ApoB lowering treatments have minimal Lp(a)-lowering efficacy. We previously shown AZD8233 inhibits hepatic PCSK9 synthesis causes substantial reductions in LDL-C. Here we report the...
Viral genotype data aid in understanding the development of antiretroviral drug resistance and identifying appropriate treatments. Using HIV-1 protease sequences measures vitro sensitivity to amprenavir, we develop a novel statistical approach that can be used investigate combinations mutations alter susceptibility. Our method is based on use order statistics whose null distributions are estimated through resampling for formal hypothesis testing. We present step-down testing preserves...
Understanding how long-term clinical outcomes relate to short-term response therapy is an important topic of research with a variety applications. In HIV, early measures viral RNA levels are known be strong prognostic indicator future load response. However, mutations observed in the high-dimensional genotype at time point may change this prognosis. Unfortunately, some subjects not have genetic sequence measured point, and missing for reasons related outcome. Complete-case analyses data...
Lanabecestat is a brain-permeable, oral inhibitor of human beta-site amyloid (Aβ) precursor protein-cleaving enzyme 1 (BACE1) that reduces Aβ production. currently under investigation as potential disease-modifying treatment for Alzheimer's disease (AD). Here we describe baseline characteristics participants randomized into the ongoing Phase 2/3 AMARANTH study which includes with Early AD (defined mild cognitive impairment (MCI) due to and dementia (mild AD)) (NCT02245737). Amyloid positive...